Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases

被引：0

作者：

Saade Abdalkareem Jasim

Alexei Valerievich Yumashev

Walid Kamal Abdelbasset

Ria Margiana

Alexander Markov

Wanich Suksatan

Benjamin Pineda

Lakshmi Thangavelu

Seyed Hossein Ahmadi

机构：

[1] Al-Maarif University College,Medical Laboratory Techniques Department

[2] Department of Prosthetic Dentistry,Department of Health and Rehabilitation Sciences, College of Applied Medical Sciences

[3] Sechenov First Moscow State Medical University,Department of Physical Therapy, Kasr Al

[4] Prince Sattam Bin Abdulaziz University,Aini Hospital

[5] Cairo University,Department of Anatomy, Faculty of Medicine

[6] Universitas Indonesia,Master’s Programme Biomedical Sciences, Faculty of Medicine

[7] Universitas Indonesia,Faculty of Nursing, HRH Princess Chulabhorn College of Medical Science

[8] Dr. Soetomo General Academic Hospital,Department of Neuroimmunology

[9] Tyumen State Medical University,Center for Transdisciplinary Research ,Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Science

[10] Industrial University,Cellular and Molecular Research Center, School of Medicine

[11] Chulabhorn Royal Academy,undefined

[12] National Institute of Neurology and Neurosurgery “Manuel Velasco Suarez” (INNN),undefined

[13] 14269,undefined

[14] Saveetha University,undefined

[15] Tehran University of Medical Sciences,undefined

来源：

Stem Cell Research & Therapy | / 13卷

关键词：

Mesenchymal stromal cell; Autoimmune diseases; Stem cell therapy; Clinical application;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The autoimmune diseases are associated with the host immune system, chronic inflammation, and immune reaction against self-antigens, which leads to the injury and failure of several tissues. The onset of autoimmune diseases is related to unbalanced immune homeostasis. Mesenchymal stem cells (MSCs) are multipotent cells which have capability to self-renew and differentiate into various cell types that exert a critical role in immunomodulation and regenerative therapy. Under the certain condition in vitro, MSCs are able to differentiate into multiple lineage such as osteoblasts, adipocytes, and neuron-like cells. Consequently, MSCs have a valuable application in cell treatment. Accordingly, in this review we present the last observations of researches on different MSCs and their efficiency and feasibility in the clinical treatment of several autoimmune disorders including rheumatoid arthritis, type 1 diabetes, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, autoimmune liver disease, and Sjogren’s syndrome.

引用

共 142 条

[61]

Aithal GP(2021)Neural stem cells derived from primitive mesenchymal stem cells reversed disease symptoms and promoted neurogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis Stem Cell Res Ther 12 499-331

[62]

Aggarwal S(2016)Hematopoietic stem cell transplantation for multiple sclerosis: is it a clinical reality? Stem Cell Res Ther 7 12-3151

[63]

Pittenger MF(2020)Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis Brain 143 3574-75

[64]

Wei Z(2018)Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis J Transl Med 16 57-92

[65]

Ghoryani M(2018)Phase I trial of intrathecal mesenchymal stem cell-derived neural progenitors in progressive multiple sclerosis EBioMedicine 29 23-2489

[66]

Álvaro-Gracia JM(2021)Mesenchymal stem cell-derived neural progenitors in progressive MS: two-year follow-up of a phase I study Neurol Neuroimmunol Neuroinflamm 8 e928-506

[67]

He X(2011)The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments Trials 12 62-45

[68]

Yang Y(2012)Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study Lancet Neurol 11 150-582382

[69]

Wang L(2010)Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis Arch Neurol 67 1187-57

[70]

Gowhari Shabgah A(2018)Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study PLoS ONE 13 e0195891-189

← 2 3 4 5 6 7 8 9 10 11 →